Related Experiment Video

Updated: Jan 31, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.0K

Nephrotoxicity of recent anti-cancer agents

Norbert Lameire1

  • 1University Hospital , 185, De Pintelaan, Gent 9000 , Belgium.

Clinical Kidney Journal
|April 11, 2015
PubMed

Insights

New cancer drugs can harm kidneys, causing side effects like kidney injury and high blood pressure. This review details kidney risks from targeted cancer therapies and androgen deprivation therapy.

Area of Science:

  • Nephrology
  • Oncology
  • Pharmacology

Background:

  • Cancer treatments can cause kidney damage, impacting patient survival and treatment efficacy.
  • Emerging anti-cancer drugs, particularly targeted therapies, present unique nephrotoxic risks.
  • Kidney complications are a significant concern in patients undergoing cancer therapy.

Purpose of the Study:

  • To review the nephrotoxic potential of novel anti-cancer drugs.
  • To focus on drugs targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways.
  • To discuss mammalian target of rapamycin (mTOR) inhibitors and their renal side effects.

Main Methods:

  • Literature review of recent anti-cancer drug nephrotoxicity.
  • Analysis of side effect profiles for VEGF/EGFR inhibitors and mTOR inhibitors.
  • Examination of acute kidney injury risk in prostate cancer patients on androgen deprivation therapy.

Main Results:

  • Common side effects include thrombotic microangiopathy (haemolytic-uraemic syndrome), proteinuria, hypertension, and hypomagnesemia.
  • Targeted therapies and mTOR inhibitors are associated with specific kidney lesions.
  • Androgen deprivation therapy increases the risk of acute kidney injury in advanced prostate cancer.

Conclusions:

  • Understanding the nephrotoxicity of modern cancer drugs is crucial for patient management.
  • Monitoring kidney function and managing side effects are essential for patients on these therapies.
  • Further research is needed to mitigate renal complications associated with cancer treatment.
Keywords:
androgen deprivation therapy and AKIanti-angiogenesis drugs and canceranti-cancer drugs and nephrotoxicity

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.5K
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

17.0K

Related Concept Videos

Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
559
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
551
Air-entraining Agents01:27

Air-entraining Agents

Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
270
Masking and Demasking Agents01:19

Masking and Demasking Agents

EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
3.6K
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
660